IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For October 2015
By Ed Miseta, Chief Editor, Clinical Leader
Below are my top three articles downloaded on Clinical Leader for the month of October 2015. In case you missed them, take this opportunity to see what everyone else was learning about patient centricity at Sanofi, transparency in clinical trials, and whether the pharma industry is really an enemy of the people…or just politicians.
Building A Culture Of Patient Centricity At Sanofi
Dr. Anne Beal has been involved in the medical community her entire career. In April 2014, she was asked to join Sanofi as its Chief Patient Officer. The past year-and-a-half has been a whirlwind of activity for her, defining the meaning of patient centricity and how it applies to pharma, while developing a culture of patient engagement within Sanofi. In this Q&A article, Beal discusses Sanofi’s vision for patient centricity, and getting individuals more engaged with the trial planning process.
Is The Pharma Industry Really An Enemy?
I consider myself to be a fan of the pharmaceutical industry. This is not simply because I write for a media group that covers the pharma industry. I feel like I was a fan even before taking on my current job. It may have started a few years ago when an ailment of old age (I’m 52) began to inconvenience me and disrupt my sleep. One little white pill taken once per day has now relieved me of that issue. So, while there are many industries that bring happiness and efficiencies into my life, only one of those industries has the potential to save the lives of patients with life-threatening illnesses and ease the suffering of others. That is the pharmaceutical industry.
Transparency In Clinical Trials: Will It Ever Be Achieved?
A lot has been said recently about transparency in clinical trials. In the EU a new regulation is about to address the issue, and CISCRP recently sent a petition letter to the FDA asking it to pass a similar regulation in this country. The petition, signed by hundreds of patients, hopes to make trials results more accessible to patients. It’s not hard to understand why a patient participating in a trial would want to know the results of the study, and whether or not they received the active drug or a placebo. But while changes might help companies with patient recruitment and retention issues, will true trial transparency ever be possible?
You might also enjoy:
Does Pharma Really Want Transparency In Clinical Trials?